CU24532B1 - Anticuerpos anti-transtiretina - Google Patents
Anticuerpos anti-transtiretinaInfo
- Publication number
- CU24532B1 CU24532B1 CU2017000096A CU20170096A CU24532B1 CU 24532 B1 CU24532 B1 CU 24532B1 CU 2017000096 A CU2017000096 A CU 2017000096A CU 20170096 A CU20170096 A CU 20170096A CU 24532 B1 CU24532 B1 CU 24532B1
- Authority
- CU
- Cuba
- Prior art keywords
- antibodies
- chain cdrs
- transtiretin
- ttr
- heavy chain
- Prior art date
Links
- 108010071690 Prealbumin Proteins 0.000 abstract 3
- 102000009190 Transthyretin Human genes 0.000 abstract 3
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 abstract 1
- 230000002776 aggregation Effects 0.000 abstract 1
- 238000004220 aggregation Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562109001P | 2015-01-28 | 2015-01-28 | |
| US201562266557P | 2015-12-11 | 2015-12-11 | |
| PCT/IB2016/050414 WO2016120809A1 (en) | 2015-01-28 | 2016-01-28 | Anti-transthyretin antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CU20170096A7 CU20170096A7 (es) | 2018-03-13 |
| CU24532B1 true CU24532B1 (es) | 2021-07-02 |
Family
ID=55361912
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2017000096A CU24532B1 (es) | 2015-01-28 | 2016-01-28 | Anticuerpos anti-transtiretina |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20160257736A1 (OSRAM) |
| EP (1) | EP3250594B1 (OSRAM) |
| JP (2) | JP6875280B2 (OSRAM) |
| KR (1) | KR102619359B1 (OSRAM) |
| CN (1) | CN107428822B (OSRAM) |
| AU (1) | AU2016210887B2 (OSRAM) |
| CA (1) | CA2974911A1 (OSRAM) |
| CO (1) | CO2017008469A2 (OSRAM) |
| CU (1) | CU24532B1 (OSRAM) |
| EA (1) | EA036048B1 (OSRAM) |
| ES (1) | ES2905311T3 (OSRAM) |
| MX (1) | MX391789B (OSRAM) |
| MY (1) | MY193674A (OSRAM) |
| PE (1) | PE20180200A1 (OSRAM) |
| SA (1) | SA517381991B1 (OSRAM) |
| SG (1) | SG11201706125QA (OSRAM) |
| TW (2) | TWI781507B (OSRAM) |
| WO (1) | WO2016120809A1 (OSRAM) |
| ZA (1) | ZA201705662B (OSRAM) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10464999B2 (en) | 2015-01-28 | 2019-11-05 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| US10633433B2 (en) | 2015-01-28 | 2020-04-28 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| TWI781507B (zh) * | 2015-01-28 | 2022-10-21 | 愛爾蘭商普羅佘納生物科技有限公司 | 抗甲狀腺素運送蛋白抗體 |
| US9879080B2 (en) | 2015-01-28 | 2018-01-30 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| EP3478715A2 (en) * | 2016-07-02 | 2019-05-08 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| WO2018007924A2 (en) * | 2016-07-02 | 2018-01-11 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| WO2018007922A2 (en) * | 2016-07-02 | 2018-01-11 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| BR112020003609A2 (pt) | 2017-09-29 | 2020-09-01 | Regeneron Pharmaceuticals, Inc. | sistema e método para formar uma emulsão |
| CN111757730A (zh) | 2017-10-06 | 2020-10-09 | 普罗塞纳生物科学有限公司 | 检测甲状腺素运载蛋白的方法 |
| WO2019071205A1 (en) * | 2017-10-06 | 2019-04-11 | Prothena Biosciences Limited | ANTI-TRANSTHYRETIN ANTIBODY |
| BR112020010483A2 (pt) | 2017-11-29 | 2020-10-20 | Prothena Biosciences Limited | formulação liofilizada de um anticorpo monoclonal contra transtirretina |
| CN113874510A (zh) * | 2019-06-04 | 2021-12-31 | 瑞泽恩制药公司 | 包括具有β滑移突变的人源化TTR基因座的非人动物和使用方法 |
| CN112816453B (zh) * | 2021-02-09 | 2022-07-08 | 黑龙江大学 | 蛋白在预测药物性能上的应用 |
| WO2025125544A1 (en) | 2023-12-15 | 2025-06-19 | Novo Nordisk A/S | Stable liquid formulations |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH652145A5 (de) | 1982-01-22 | 1985-10-31 | Sandoz Ag | Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen. |
| US4634666A (en) | 1984-01-06 | 1987-01-06 | The Board Of Trustees Of The Leland Stanford Junior University | Human-murine hybridoma fusion partner |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| EP0279582A3 (en) | 1987-02-17 | 1989-10-18 | Pharming B.V. | Dna sequences to target proteins to the mammary gland for efficient secretion |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| ATE356869T1 (de) | 1990-01-12 | 2007-04-15 | Amgen Fremont Inc | Bildung von xenogenen antikörpern |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| ES2139598T3 (es) | 1990-07-10 | 2000-02-16 | Medical Res Council | Procedimientos para la produccion de miembros de parejas de union especifica. |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| CA2089661C (en) | 1990-08-29 | 2007-04-03 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5858657A (en) | 1992-05-15 | 1999-01-12 | Medical Research Council | Methods for producing members of specific binding pairs |
| DE69230142T2 (de) | 1991-05-15 | 2000-03-09 | Cambridge Antibody Technology Ltd. | Verfahren zur herstellung von spezifischen bindungspaargliedern |
| DE122004000008I1 (de) | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanisierter Heregulin Antikörper. |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US5877218A (en) | 1994-01-10 | 1999-03-02 | Teva Pharmaceutical Industries, Ltd. | Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives |
| US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
| DE19539493A1 (de) | 1995-10-24 | 1997-04-30 | Thomae Gmbh Dr K | Starker homologer Promotor aus Hamster |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| US6114148C1 (en) | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
| US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
| ATE490518T1 (de) | 1999-02-05 | 2010-12-15 | Samsung Electronics Co Ltd | Verfahren und vorrichtung zum wiederauffinden von texturbildern |
| TWI255272B (en) | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
| EP1470146B8 (en) | 2001-12-28 | 2007-09-12 | Amgen Fremont Inc. | Antibodies against the muc18 antigen |
| ES2293096T3 (es) | 2002-11-29 | 2008-03-16 | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG | Nuevos genes de la fosfotransferasa de neomicina y procedimiento para la seleccion de celulas recombinantes de produccion elevada. |
| DE10338531A1 (de) | 2003-08-19 | 2005-04-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Reklonierung von Produktionszellen |
| JP4620739B2 (ja) | 2004-11-10 | 2011-01-26 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | Ｃｈｏ細胞に対する細胞保存戦略を最適化するためのフローサイトメトリ分析の使用 |
| WO2007124345A2 (en) | 2006-04-21 | 2007-11-01 | The Government Of The United States, As Represented By The Secretary Of Health And Human Services | Beta-amyloid pet imaging agents |
| US20080124760A1 (en) | 2006-07-26 | 2008-05-29 | Barbara Enenkel | Regulatory Nucleic Acid Elements |
| CA2699837C (en) | 2006-12-01 | 2017-06-13 | Seattle Genetics, Inc. | Variant target binding agents and uses thereof |
| JP5467415B2 (ja) | 2007-03-02 | 2014-04-09 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | タンパク質製造の改良 |
| EP2031064A1 (de) | 2007-08-29 | 2009-03-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | Verfahren zur Steigerung von Proteintitern |
| WO2010030203A1 (en) | 2008-09-09 | 2010-03-18 | Biocodex - Incubação De Empresas De Ciências Da Vida, S.A. | Monoclonal antibody to human amyloidogenic and modified forms of transthyretin and its use in the detection and treatment of fap and pathologies presenting modified ttr |
| US9534048B2 (en) * | 2012-08-24 | 2017-01-03 | University Health Network | Antibodies to TTR and methods of use |
| US9790269B2 (en) * | 2013-02-08 | 2017-10-17 | Misfolding Diagnostics, Inc. | Transthyretin antibodies and uses thereof |
| TWI781507B (zh) | 2015-01-28 | 2022-10-21 | 愛爾蘭商普羅佘納生物科技有限公司 | 抗甲狀腺素運送蛋白抗體 |
-
2016
- 2016-01-27 TW TW110100084A patent/TWI781507B/zh active
- 2016-01-27 TW TW105102534A patent/TWI718121B/zh not_active IP Right Cessation
- 2016-01-28 PE PE2017001286A patent/PE20180200A1/es unknown
- 2016-01-28 WO PCT/IB2016/050414 patent/WO2016120809A1/en not_active Ceased
- 2016-01-28 ES ES16704940T patent/ES2905311T3/es active Active
- 2016-01-28 KR KR1020177023748A patent/KR102619359B1/ko active Active
- 2016-01-28 CN CN201680015800.8A patent/CN107428822B/zh active Active
- 2016-01-28 AU AU2016210887A patent/AU2016210887B2/en active Active
- 2016-01-28 US US15/009,666 patent/US20160257736A1/en not_active Abandoned
- 2016-01-28 EP EP16704940.2A patent/EP3250594B1/en active Active
- 2016-01-28 CA CA2974911A patent/CA2974911A1/en active Pending
- 2016-01-28 JP JP2017540249A patent/JP6875280B2/ja active Active
- 2016-01-28 CU CU2017000096A patent/CU24532B1/es unknown
- 2016-01-28 MY MYPI2017702749A patent/MY193674A/en unknown
- 2016-01-28 SG SG11201706125QA patent/SG11201706125QA/en unknown
- 2016-01-28 MX MX2017009804A patent/MX391789B/es unknown
- 2016-01-28 EA EA201791711A patent/EA036048B1/ru unknown
-
2017
- 2017-07-26 SA SA517381991A patent/SA517381991B1/ar unknown
- 2017-08-21 ZA ZA2017/05662A patent/ZA201705662B/en unknown
- 2017-08-22 CO CONC2017/0008469A patent/CO2017008469A2/es unknown
-
2021
- 2021-04-22 JP JP2021072547A patent/JP7219928B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2974911A1 (en) | 2016-08-04 |
| MX391789B (es) | 2025-03-21 |
| MX2017009804A (es) | 2018-08-15 |
| US20160257736A1 (en) | 2016-09-08 |
| SG11201706125QA (en) | 2017-08-30 |
| BR112017016324A2 (pt) | 2018-03-27 |
| JP2018509889A (ja) | 2018-04-12 |
| CO2017008469A2 (es) | 2018-01-16 |
| EP3250594A1 (en) | 2017-12-06 |
| ES2905311T3 (es) | 2022-04-07 |
| TWI781507B (zh) | 2022-10-21 |
| CU20170096A7 (es) | 2018-03-13 |
| MY193674A (en) | 2022-10-24 |
| CN107428822A (zh) | 2017-12-01 |
| JP7219928B2 (ja) | 2023-02-09 |
| ZA201705662B (en) | 2018-08-29 |
| EA036048B1 (ru) | 2020-09-18 |
| TW201636372A (zh) | 2016-10-16 |
| EA201791711A1 (ru) | 2017-11-30 |
| AU2016210887A1 (en) | 2017-08-10 |
| KR102619359B1 (ko) | 2024-01-02 |
| EP3250594B1 (en) | 2021-11-17 |
| TW202118782A (zh) | 2021-05-16 |
| SA517381991B1 (ar) | 2021-12-13 |
| KR20170120607A (ko) | 2017-10-31 |
| JP6875280B2 (ja) | 2021-05-26 |
| CN107428822B (zh) | 2021-11-23 |
| TWI718121B (zh) | 2021-02-11 |
| JP2021129562A (ja) | 2021-09-09 |
| PE20180200A1 (es) | 2018-01-31 |
| AU2016210887B2 (en) | 2021-11-04 |
| WO2016120809A1 (en) | 2016-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU24532B1 (es) | Anticuerpos anti-transtiretina | |
| CY1122245T1 (el) | Pd-1 αντισωμα, θραυσμα δεσμευσης αντιγονου αυτου, και ιατρικη εφαρμογη αυτου | |
| CY1124771T1 (el) | Αντισωματα εναντι-σορτιλiνης και μεθοδοι χρησης αυτων | |
| CY1122840T1 (el) | Ανθρωποποιημενα ή χιμαιρικα αντισωματα cd3 | |
| CO2017013356A2 (es) | Anticuerpos de factor xi | |
| CL2018001177A1 (es) | Anticuerpos vinculados especificamente a pd-1 y sus usos. | |
| PE20190970A1 (es) | Anticuerpos anti-cd40 y sus usos | |
| EA201890305A1 (ru) | Гуманизированные или химерные cd3-антитела | |
| EA201692458A1 (ru) | Анти-gitr антитела и способы их применения | |
| ZA201803079B (en) | Anti-dr5 antibodies and methods of use thereof | |
| AR109715A1 (es) | Anticuerpos anti-cd27 | |
| ES2687282T3 (es) | Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos | |
| NZ728749A (en) | Anti-pd-l1 antibodies | |
| EA201791270A1 (ru) | Модифицированные april-связывающие антитела | |
| EA201500995A1 (ru) | Биспецифические антитела, специфические в отношении fap и dr5, антитела, специфические в отношении dr5, и способы их применения | |
| PE20171180A1 (es) | Anticuerpos anti-pd-1 y sus metodos de uso | |
| CL2015001895A1 (es) | Anticuerpos que se unen al tl1a y sus usos | |
| CY1125400T1 (el) | Νεα αντι-ανθρωπινα αντισωματα gpvi και χρησεις αυτων | |
| AR100680A1 (es) | Anticuerpos anti-dr5 y moléculas que comprenden dominios de unión de dr5 de los mismos | |
| CY1121158T1 (el) | Αντισωμα ικανο να αναγνωριζει ειδικα υποδοχεα τρανσφερρινης | |
| AR100978A1 (es) | LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS | |
| MX381139B (es) | Anticuerpo anti-notch4 humano. | |
| CL2017000912A1 (es) | Anticuerpos que se unen a ccr6 y sus usos | |
| MX2020008730A (es) | Regímenes de dosificación de anticuerpo b7-h4. | |
| PH12015501650A1 (en) | Human antibody specific to human metapneumovirus, or antigen-binding fragment thereof |